Infinity Pharmaceuticals (INFI) 15.13 $INFI
Infinity Announces the Date of Its Full-Year 2014 Financial Results Conference Call and Webcast
Business Wire - Tue Feb 10, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, February 24, 2015, at 4:30 p.m. ET. During the call, management will review the company's full-year 2014 financial results and provide an update on Infinity's business.
INFI: 15.13 (+0.55)
Will Thoratec (THOR) Miss Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 3:42PM CST
Our proven model does not conclusively show that Thoratec Corp. (THOR) is likely to beat earnings this quarter.
ACT: 285.37 (+3.71), THOR: 40.01 (+0.54), INFI: 15.13 (+0.55), HLS: 45.01 (+0.30)
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)
Infinity Pharmaceuticals Has Returned 33.2% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Wed Jan 28, 4:40PM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 6 months, Infinity Pharmaceuticals has returned 33.21% as of today's recent price of $14.98.
INFI: 15.13 (+0.55)
This Stock Could Become the Next Johnson & Johnson
Motley Fool Staff - Motley Fool - Sat Jan 24, 7:01AM CST
There's little debate that healthcare goliath Johnson & Johnson has become the de facto gold standard among healthcare companies. J&J's Tylenol and Band-Aid brands are household staples, its prescription drugs are among the most widely...
ABT: 46.09 (+0.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), GOOG: 549.01 (+6.08), NVS: 102.20 (-0.17)
31.0% Return Seen to Date on SmarTrend Infinity Pharmaceuticals Call (INFI)
Comtex SmarTrend(R) - Wed Jan 21, 11:02AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 5 months, Infinity Pharmaceuticals has returned 30.99% as of today's recent price of $14.73.
INFI: 15.13 (+0.55)
Infinity Pharmaceuticals Up 37.8% Since SmarTrend Uptrend Call (INFI)
Comtex SmarTrend(R) - Wed Jan 14, 9:37AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 5 months, Infinity Pharmaceuticals has returned 37.75% as of today's recent price of $15.49.
INFI: 15.13 (+0.55)
Infinity Provides Key 2015 Goals and Financial Guidance
Business Wire - Mon Jan 12, 7:01AM CST
--- Topline Data from DYNAMO Anticipated in the Second Half of 2015 -
INFI: 15.13 (+0.55)
High Alpha In Shorting Infinity Pharmaceuticals With Potential Failure Of Upcoming Trials
Kanak Kanti De - at Seeking Alpha - Sat Jan 10, 8:44AM CST
INFI: 15.13 (+0.55)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), ALKS: 71.40 (-1.89), CELG: 115.88 (+0.16), AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), JPM: 59.67 (+0.10), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Infinity Pharmaceuticals Falls on Duvelisib Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:00PM CST
Infinity Pharmaceuticals' (INFI) duvelisib failed to meet the primary endpoint in a phase II study conducted in moderate-to-severe rheumatoid arthritis patients.
SHPG: 239.82 (+6.11), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), BIOD: 1.38 (-0.14)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
NVEE: 12.60 (+0.05), ENPH: 15.15 (+0.37), PODD: 32.00 (-0.07), BWEN: 5.48 (+0.15), SGMS: 14.15 (+0.36), WATT: 9.43 (+0.01), MARPS: 11.70 (+0.10), INFI: 15.13 (+0.55), JST: 5.35 (+0.14)
Costco and Apollo Education are big market movers
AP - Thu Jan 08, 3:44PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
MU: 31.85 (-0.09), MON: 124.77 (+2.00), DKS: 53.95 (+0.47), GMCR: 118.53 (+0.56), STZ: 113.03 (-0.48), BKS: 24.51 (+0.07), ARO: 3.63 (+0.04), STZ.B: 112.58 (-0.82), SONC: 31.59 (-0.37), S: 5.23 (+0.08), COST: 147.10 (-0.66), INFI: 15.13 (+0.55), RPM: 49.79 (-0.11), APOL: 25.97 (+0.33), ARNA: 4.55 (+0.02), BKE: 49.59 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:47AM CST
ELOS: 10.16 (+0.07), MBII: 3.88 (+0.33), PDFS: 18.31 (+0.04), CASM: 1.36 (-0.01), PHMD: 1.68 (+0.04), EPRS: 7.67 (+0.67), BIND: 6.06 (+0.21), JOB: 0.79 (+0.01), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), ARO: 3.63 (+0.04), PODD: 32.00 (-0.07), AOI: 1.05 (+0.03), BWEN: 5.48 (+0.15), NBIX: 37.22 (+0.27), VLCCF: 4.15 (-0.06), NEFF: 10.43 (-0.04), PSTR: 4.63 (+0.14), INFI: 15.13 (+0.55), APOL: 25.97 (+0.33)
Infinity Pharma drops after Phase 2 fails
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:25AM CST
INFI: 15.13 (+0.55)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Ahead of the Bell: Infinity Pharmaceuticals shares slide
AP - Thu Jan 08, 7:22AM CST
CAMBRIDGE, Mass. (AP) — Infinity Pharmaceuticals will stop studying one of its potential drugs as a rheumatoid arthritis treatment after it failed to generate enough improvement in patients during a mid-stage study.
INFI: 15.13 (+0.55)
Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis
Business Wire - Thu Jan 08, 5:50AM CST
--- Infinity to Continue Focusing Its Efforts on the Development of Duvelisib in Blood Cancers -
INFI: 15.13 (+0.55)
Uptrend Call Working As Infinity Pharmaceuticals Stock Rises 45.6% (INFI)
Comtex SmarTrend(R) - Wed Jan 07, 9:04AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 5 months, Infinity Pharmaceuticals has returned 45.58% as of today's recent price of $16.37.
INFI: 15.13 (+0.55)
Infinity Announces the Date of Its Full-Year 2014 Financial Results Conference Call and Webcast
Business Wire - Tue Feb 10, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, February 24, 2015, at 4:30 p.m. ET. During the call, management will review the company's full-year 2014 financial results and provide an update on Infinity's business.
INFI: 15.13 (+0.55)
Will Thoratec (THOR) Miss Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 3:42PM CST
Our proven model does not conclusively show that Thoratec Corp. (THOR) is likely to beat earnings this quarter.
ACT: 285.37 (+3.71), THOR: 40.01 (+0.54), INFI: 15.13 (+0.55), HLS: 45.01 (+0.30)
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)
Infinity Pharmaceuticals Has Returned 33.2% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Wed Jan 28, 4:40PM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 6 months, Infinity Pharmaceuticals has returned 33.21% as of today's recent price of $14.98.
INFI: 15.13 (+0.55)
This Stock Could Become the Next Johnson & Johnson
Motley Fool Staff - Motley Fool - Sat Jan 24, 7:01AM CST
There's little debate that healthcare goliath Johnson & Johnson has become the de facto gold standard among healthcare companies. J&J's Tylenol and Band-Aid brands are household staples, its prescription drugs are among the most widely...
ABT: 46.09 (+0.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), GOOG: 549.01 (+6.08), NVS: 102.20 (-0.17)
31.0% Return Seen to Date on SmarTrend Infinity Pharmaceuticals Call (INFI)
Comtex SmarTrend(R) - Wed Jan 21, 11:02AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 5 months, Infinity Pharmaceuticals has returned 30.99% as of today's recent price of $14.73.
INFI: 15.13 (+0.55)
Infinity Pharmaceuticals Up 37.8% Since SmarTrend Uptrend Call (INFI)
Comtex SmarTrend(R) - Wed Jan 14, 9:37AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 5 months, Infinity Pharmaceuticals has returned 37.75% as of today's recent price of $15.49.
INFI: 15.13 (+0.55)
Infinity Provides Key 2015 Goals and Financial Guidance
Business Wire - Mon Jan 12, 7:01AM CST
--- Topline Data from DYNAMO Anticipated in the Second Half of 2015 -
INFI: 15.13 (+0.55)
High Alpha In Shorting Infinity Pharmaceuticals With Potential Failure Of Upcoming Trials
Kanak Kanti De - at Seeking Alpha - Sat Jan 10, 8:44AM CST
INFI: 15.13 (+0.55)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), ALKS: 71.40 (-1.89), CELG: 115.88 (+0.16), AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), JPM: 59.67 (+0.10), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Infinity Pharmaceuticals Falls on Duvelisib Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:00PM CST
Infinity Pharmaceuticals' (INFI) duvelisib failed to meet the primary endpoint in a phase II study conducted in moderate-to-severe rheumatoid arthritis patients.
SHPG: 239.82 (+6.11), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), BIOD: 1.38 (-0.14)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
NVEE: 12.60 (+0.05), ENPH: 15.15 (+0.37), PODD: 32.00 (-0.07), BWEN: 5.48 (+0.15), SGMS: 14.15 (+0.36), WATT: 9.43 (+0.01), MARPS: 11.70 (+0.10), INFI: 15.13 (+0.55), JST: 5.35 (+0.14)
Costco and Apollo Education are big market movers
AP - Thu Jan 08, 3:44PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
MU: 31.85 (-0.09), MON: 124.77 (+2.00), DKS: 53.95 (+0.47), GMCR: 118.53 (+0.56), STZ: 113.03 (-0.48), BKS: 24.51 (+0.07), ARO: 3.63 (+0.04), STZ.B: 112.58 (-0.82), SONC: 31.59 (-0.37), S: 5.23 (+0.08), COST: 147.10 (-0.66), INFI: 15.13 (+0.55), RPM: 49.79 (-0.11), APOL: 25.97 (+0.33), ARNA: 4.55 (+0.02), BKE: 49.59 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:47AM CST
ELOS: 10.16 (+0.07), MBII: 3.88 (+0.33), PDFS: 18.31 (+0.04), CASM: 1.36 (-0.01), PHMD: 1.68 (+0.04), EPRS: 7.67 (+0.67), BIND: 6.06 (+0.21), JOB: 0.79 (+0.01), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), ARO: 3.63 (+0.04), PODD: 32.00 (-0.07), AOI: 1.05 (+0.03), BWEN: 5.48 (+0.15), NBIX: 37.22 (+0.27), VLCCF: 4.15 (-0.06), NEFF: 10.43 (-0.04), PSTR: 4.63 (+0.14), INFI: 15.13 (+0.55), APOL: 25.97 (+0.33)
Infinity Pharma drops after Phase 2 fails
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:25AM CST
INFI: 15.13 (+0.55)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Ahead of the Bell: Infinity Pharmaceuticals shares slide
AP - Thu Jan 08, 7:22AM CST
CAMBRIDGE, Mass. (AP) — Infinity Pharmaceuticals will stop studying one of its potential drugs as a rheumatoid arthritis treatment after it failed to generate enough improvement in patients during a mid-stage study.
INFI: 15.13 (+0.55)
Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis
Business Wire - Thu Jan 08, 5:50AM CST
--- Infinity to Continue Focusing Its Efforts on the Development of Duvelisib in Blood Cancers -
INFI: 15.13 (+0.55)
Uptrend Call Working As Infinity Pharmaceuticals Stock Rises 45.6% (INFI)
Comtex SmarTrend(R) - Wed Jan 07, 9:04AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 5 months, Infinity Pharmaceuticals has returned 45.58% as of today's recent price of $16.37.
INFI: 15.13 (+0.55)
